The parties intend to evaluate a broader collaboration following the outcome of the ongoing validation work conducted together with Amsterdam UMC, with initial results expected during the third quarter of 2026.

“The signing of this Letter of Intent confirms that our diagnostic program is attracting interest from leading players in the global diagnostics industry. Establishing a framework with Fujirebio at this stage is highly encouraging and reinforces our belief that the unique biology behind our oligomer technology has the potential to create value not only through therapeutics, but also through diagnostics. We now look forward to completing the ongoing validation work and taking the next steps towards a potential commercial partnership,” says Tord Labuda, CEO of Alzinova.

The contemplated collaboration concerns the further development, optimization, validation and potential commercialization of a blood-based diagnostic test designed to measure naturally occurring (endogenous) antibodies against toxic amyloid-β oligomers. The test is based on Alzinova’s proprietary Aβ42CC oligomer technology, which is also the foundation of the Company’ s therapeutic vaccine candidate ALZ-101.

“As a recognized leader in Alzheimer’s disease diagnostics and at the forefront of innovation in neurodegenerative diseases, Fujirebio continuously evaluates novel approaches that can improve disease management and support better clinical decision-making. We see potential in Alzinova’s differentiated technology and look forward to assessing the results from the ongoing validation work as a basis for a possible future collaboration,” says Christian Fermer, CEO of Fujirebio Diagnostics.